POLE3

Across TCGA pan-cancer cohorts, POLE3 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated POLE3 data layer compared with 24 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher POLE3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated POLE3 expression acts as an unfavorable survival marker, although some lineages such as LSCC and PDAC show a favorable association.

LSCC, PDAC, and GBM are the cancer types where POLE3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	II,III,IV	0.856	0.516	.003	26	view →
PDAC	DFS	Median	IV	0.785	0.214	.006	11	view →
GBM	OS	Median	All	0.282	0.486	.010	9	view →
HNSC	OS	Quartile	All	0.776	0.948	.010	9	view →
OV	DFS	Tertile	All	0.781	1.000	.021	8	view →
LUAD	OS	Tertile	III,IV	0.331	0.759	.038	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

POLE3–LSCC (DFS)

Open the LSCC breakdown →